Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 77Thoracic 29Head & Neck 12Lymphoid 6Gynecologic 5Other solid neoplasm 3Genitourinary 3CNS 3Breast 3Tumor-Agnostic 2Endocrine 2Sarcoma 1Other neoplasm 1NET 1Myeloid 1Dermatologic 1

Conditions

Lymphoma, Extranodal NK-T-Cell 1Lymphohistiocytosis, Hemophagocytic 1

Interventions

Imatinib Mesylate 17Cytarabine 13Azacitidine 13Cyclophosphamide 11Decitabine 9Dasatinib 9Etoposide 8nilotinib 7Peripheral Blood Stem Cell Transplantation 7Busulfan 7Tacrolimus 6Polymerase Chain Reaction 6Idarubicin 6Blood Specimen Collection 6Antilymphocyte Serum 6fludarabine phosphate 5Mycophenolic Acid 5Melphalan 5ruxolitinib 4pegaspargase 4fludarabine 4Whole-Body Irradiation 4Radiotherapy 4Methylprednisolone 4Hydroxyurea 4Filgrastim 4ponatinib 3Surveys and Questionnaires 3Rituximab 3Lenalidomide 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × sintilimab × Myeloid × Clear all
NCT05008666 2021-08-17

Induction Chemotherapy Sequential Sintilimab Combined With Dual Epigenetic Drugs for ENKTL-HLH

Sun Yat-sen University

Phase 2 Unknown
37 enrolled
LymphoidMyeloid

Lymphohistiocytosis, Hemophagocytic, Lymphoma, Extranodal NK-T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡